Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses the next steps and future development for vyxeos in AML, which include a better understanding of the drug and its impact on overall survival in other subsets of AML.
WhatÂ’s the Next Step for Vyxeos in AML?
